LungLife AI, INC Notice of Results (1156I)
2023年8月3日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMLLAI
RNS Number : 1156I
LungLife AI, INC
03 August 2023
LungLife AI, Inc.
(the "Company" or "LungLife")
Notice of Results
Investor Presentation
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for the early detection of lung cancer, will announce its
unaudited half-year report for the six months ended 30 June 2023 on
Tuesday 8 August 2023.
Investor presentation
Paul Pagano, Chief Executive Officer, and David Anderson, Chief
Financial Officer, will be hosting a live online presentation
relating to the half-year report via the Investor Meet Company
platform at 4.30pm (BST) on Tuesday 8 August 2023.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and
register for the presentation here . Investors who already follow
LungLife on the Investor Meet Company platform will automatically
be invited.
A recording of the presentation and a PDF of the slides used
will also be available on the LungLife website:
https://investors.lunglifeai.com/media/
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& Joint Broker)
Virginia Bull / Cameron MacRitchie
/ Lydia Zychowska
Goodbody (Joint Broker) Tel: +44 (0) 20 3841 6202 / +353 (1)
Tom Nicholson / Stephen Kane 667 0420
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 /
Marriage 07867 984 082
About LungLife
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSSFFIEEDSEDA
(END) Dow Jones Newswires
August 03, 2023 02:00 ET (06:00 GMT)
Lunglife Ai (LSE:LLAI)
過去 株価チャート
から 4 2024 まで 5 2024
Lunglife Ai (LSE:LLAI)
過去 株価チャート
から 5 2023 まで 5 2024